Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma
<i>CDKN2A/B</i> homozygous deletion and midline involvement independently reduce PFS in patients with grade 4 IDH-mutant astrocytoma treated with standard radiation/temozolomide. Furthermore, midline involvement may be associated with aberrant retinoblastoma signaling. These findings suggest that radiographic and molecular features may have potential utility in informing clinical trial stratification and guiding early clinical decision-making. However, our findings are limited by our small sample size, so further validation in larger, prospective cohorts is needed.
Authors
- Terry C. Burns (ORCID: https://orcid.org/0000-0001-7633-3045)
- Aditya Raghunathan (ORCID: https://orcid.org/0000-0001-6198-7441)
- Thomas M. Kollmeyer (ORCID: https://orcid.org/0000-0002-0694-3224)
- Cristiane M. Ida (ORCID: https://orcid.org/0000-0003-2768-2913)
- Sani H. Kizilbash (ORCID: https://orcid.org/0000-0001-8568-1519)
- Rachael A. Vaubel (ORCID: https://orcid.org/0000-0001-8842-5975)
- Kristen Drucker (ORCID: https://orcid.org/0000-0001-6244-5863)
- Muhammad Asad Maqbool (ORCID: https://orcid.org/0000-0003-2798-7725)
- Daniel H. Lachance (ORCID: https://orcid.org/0000-0002-5475-9931)
- Robert B. Jenkins (ORCID: https://orcid.org/0000-0002-4049-694X)
- Paul A. Decker (ORCID: https://orcid.org/0000-0002-3756-4227)
- Caterina Giannini (ORCID: https://orcid.org/0000-0003-2757-6782)
- Jeanette E. Eckel-Passow (ORCID: https://orcid.org/0009-0001-5176-6378)
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1212/wnl.0000000000214478
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00